Table 10. c.(375G>A) and clinical features in 45 patients with missense mutations.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Clinical features | N | c.(375G>A) | | X2 | P |
| With Without | |
| Age |  |  |  |  |  |
| ≤45  >45 | 16  29 | 11(68.75%)  4(13.79%) | 5(31.25%)  25(86.21%) |  | 0.001 |
|  |  |  |  |  |  |
| Tumor size |  |  |  |  |  |
| ≤ 2cm | 23 | 7(30.43%) | 16(69.57%) |  |  |
| >2cm, ≤ 5cm  >5cm | 18  4 | 7(38.89%)  1(25.00%) | 11(61.11%)  3(75.00%) | 0.532 | 0.894 |
|  |  |  |  |  |  |
| Clinical stage |  |  |  |  |  |
| I, II | 9 | 2(22.22%) | 7(77.78%) |  |  |
| III，IV | 36 | 13(36.11%) | 23(63.89%) |  | 0.695 |
| Molecular subtype |  |  |  |  |  |
| Luminal A | 15 | 3(20.00%) | 12(80.00%) |  |  |
| Luminal B | 12 | 3(25.00%) | 9(75.00%) |  |  |
| HER-2+ | 5 | 1(20.00%) | 4(80.00%) |  |  |
| TNBC | 13 | 8(61.54%) | 5(38.46%) |  | 0.104 |
| Lymph-node metastasis |  |  |  |  |  |
| Yes | 27 | 11(40.74%) | 16(59.26%) |  |  |
| No | 18 | 4(22.44%) | 14(77.56%) |  | 0.333 |
|  |  |  |  |  |  |
| ER |  |  |  |  |  |
| +  - | 27  18 | 6(22.22%)  9(50.00%) | 21(77.78%)  9(50.00%) |  | 0.105 |
|  |  |  |  |  |  |
| PR  +  - | 15  30 | 3(20.00%)  12(40.00%) | 12(80.00%)  18(60.00%) |  | 0.315 |
|  |  |  |  |  |  |
| HER2  + | 12 | 1(8.33%) | 11(91.67%) |  |  |
| - | 33 | 14(42.42%) | 19(57.58%) |  | 0.038 |
|  |  |  |  |  |  |
| Ki-67 |  |  |  |  |  |
| ≤30% | 23 | 7(30.43%) | 16(69.57%) |  |  |
| >30% | 22 | 8(36.36%) | 14(63.64%) | 0.178 | 0.673 |

P-value <0.05, statistically significant.